

Pediatric Nephrology Society of the Philippines (PNSP) Guidelines on COVID 19-vaccination of pediatric kidney patients 12 to 18 years old October 14, 2021

#### Disclaimer:

The following guidelines are based on the limited available data.

These guidelines shall be revisited regularly and updated as necessary.

## **Situational Background**

### **Coronavirus Disease (COVID)**

As of October 14, 2021, from World meter, there are **240,021,214** Coronavirus cases reported with **4,891,285** or 2% deaths worldwide. In the Philippines, there now **2,698,232** documented cases with **40,221** deaths or 1.5%.



UNICEF data showed that children and adolescents under 20 years of age accounts for 14% of reported COVID cases with around 0.4% deaths. In the local setting, from the start of the pandemic until August 2021, DOH recorded 183,747 pediatric COVID cases, 0-19 years of age. This is around 10% of the total COVID cases with 520 confirmed deaths.





## **Pediatric COVID cases with kidney disease:**

On behalf of the COVID-19 Task Force of the Italian Society of Pediatric Nephrology, Mastrangelo et al in August 2021 did a study on the incidence of COVID-19 infection among pediatric kidney patients. Of the 1572 participants, with a median age of 11.1 years, there were only 3 or 0.19% with confirmed COVID 19 infection.

From the National Kidney and Transplant Institute, the study of Ancheta et al, reported that out of 517 pediatric CKD patients admitted last year, 2% or 15 cases had COVID positive infections. On follow up, from the start of the pandemic up to June 2021, of the 686 admissions there now 5% or 33 reported COVID cases.

#### **Interim**

With the ongoing threat of COVID 19 infection, PNSP reviewed the international and local data on the efficacy and safety of COVID 19 vaccination on pediatric patients with kidney disease and formulated its recommendations. Last October 12, PNSP conducted an interactive session with its members together with experts from pediatric Allergology-Immunology, Infectious Disease and Cardiology specialties.

October 15, 2021, is the start of COVID 19 vaccination among children ages 12-17 years and the Pediatric Nephrology Society of the Philippines would like to share the PNSP Guidelines on COVID 19-vaccination of pediatric kidney patients 12 to 18 years old.

		THE PARTY OF THE P
Questions	PNSP Recommendations	Sources
1. Is COVID-19 vaccination recommended for pediatric patients with kidney disease?	Yes. COVID-19 vaccination is NOT CONTRAINDICATED among pediatric kidney patients ages 12-18 years old who are: on immunosuppressants, diagnosed with CKD; on dialysis; post kidney transplants and who had COVID-19 infection.	http://www.bccdc.ca/Health-Info-Site/Documents/COVID- 19_vaccine/Kidney_disease_Clinical_G uidance.pdf  https://www.kidneyfund.org/covid- 19/vaccine-faqs/
2. What COVID-19 vaccines are recommended for pediatric patients with kidney disease?	Pfizer-BioNTech (BNT162b2) Moderna (mRNA-1273) AstraZeneca/COVISHIELD (ChADOx1-S) * Johnson & Johnson vaccine*  * No recommendation yet from DOH, Philippines	http://www.bccdc.ca/Health-Info- Site/Documents/COVID- 19 vaccine/Kidney disease Clinical G uidance.pdf  https://www.kidneyfund.org/covid- 19/vaccine-faqs/

Questions	PNSP Recommendations	Sources
3. How many doses of COVID-19 vaccine do pediatric patients with kidney disease need?	2 doses for most, with a minimum interval of 28 days between the 1 <sup>st</sup> and 2 <sup>nd</sup> dose, but for some, may need a 3 <sup>rd</sup> dose	http://www.bccdc.ca/Health-Info- Site/Documents/COVID-  19 vaccine/Kidney disease Clinical Guida nce.pdf
	A minimum interval of 28 days between dose 2 and dose 3 is recommended for those eligible for a third dose.*	https://www.gla.ac.uk/news/headline 808 086 en.html
	Note: Some studies demonstrate that some people who are immunocompromised develop an improved antibody response after a third dose of vaccine	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245347/  https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html
	Moderna COVID-19 vaccine is preferred for the third dose. However, if Moderna is unavailable (or if the individual prefers), the Pfizer-BioNtech COVID-19 vaccine may be provided.	https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html https://www.reuters.com/business/healthc
	*No recommendation yet from DOH, Philippines as to the 3 <sup>rd</sup> dose	are-pharmaceuticals/who-advises- additional-covid-shot- immunocompromised-people-2021-10-11/

		THE WITH SWITH SHIP
Questions	PNSP Recommendations	Sources Sources
4. Are there specific contraindications for COVID-19 vaccination on pediatric patients with kidney disease?	The risk of allergic reaction is the same with the general population. For those with history of anaphylaxis of unknown cause or those with suspected allergy to COVID-19 vaccine components, there is a need for allergology clearance prior to immunization	http://www.bccdc.ca/Health- Info-Site/Documents/COVID- 19 vaccine/Kidney disease Cli nical_Guidance.pdf
5. For pediatric patients on immunosuppressants, do they need to withhold these medications prior to COVID - 19 immunization?	Recommendations for patients on immunosuppressants are based on extrapolated data from other viral infections, immunology of immunizations and from expert opinion.  Patients who need to receive immunosuppressive therapy (Rituximab, Prednisone 20 mg/day or greater, Cyclophosphamide or Plasma Exchange) should complete the course of treatment first before receiving the vaccine.  For life-threatening conditions, treatment should not be delayed in order to be immunized.	http://www.bccdc.ca/Health-Info-Site/Documents/COVID- 19 vaccine/Kidney disease Clinical Guidance.pdf

PNSP Recommendations	Sources
For patients on Rituximab therapy: To optimize vaccine response, COVID 19 immunization should ideally be given 4 to 5 months after their last infusion and 2 to 4 weeks prior to next infusion if possible.  For patients on prednisone: 20mg/day or higher (or equivalents): Consider waiting until prednisone dose is tapered to below 20mg/day to receive both vaccine doses.	http://www.bccdc.ca/Health-Info-Site/Documents/COVID-  19 vaccine/Kidney disease Clinical Guidance.p  df
COVID-19 vaccines can be given concomitantly with, or any time before or after any other indicated vaccine.  It has been demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.	ttp://www.bccdc.ca/Health-Info-Site/Documents/COVID- 19_vaccine/Kidney_disease_Clinical_Guidance.p df  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines- us.html?CDC_AA_refVal=https%3A%2F%2Fwww .cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-
	For patients on Rituximab therapy: To optimize vaccine response, COVID 19 immunization should ideally be given 4 to 5 months after their last infusion and 2 to 4 weeks prior to next infusion if possible.  For patients on prednisone: 20mg/day or higher (or equivalents): Consider waiting until prednisone dose is tapered to below 20mg/day to receive both vaccine doses.  COVID-19 vaccines can be given concomitantly with, or any time before or after any other indicated vaccine.  It has been demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously

Questions	PNSP Recommendations	Sources
7. What to do on pediatric patients diagnosed with kidney disease associated with hypertension?	Vaccine recipients with blood pressure (BP) not meeting definitions of hypertensive emergency and without symptoms like chest pain, headaches or pain on the nape may be given immunization.	https://doh.gov.ph/press- release/DOH-ISSUES- ADDITIONAL-VACCINATION- GUIDELINES
	Those with hypertension should take their medication before getting vaccinated.  If BP remains too high, a doctor should be consulted first.	Philippine Society of Hypertension and Philippine Heart Association Guidelines
8. What are the reported vaccine side effects among pediatric patients with kidney disease?	Side effects are the same with the general population such as pain and swelling from the vaccination site; fever, chills, feeling of tiredness or headache.	https://www.kidney.org/coronav irus/vaccines-kidney- disease#side-effects
9. Is COVID 19 immunization safe and effective in pediatric kidney patients with coexisting cardiomyopathy?	Consider immunization for the following conditions: -Functional Class 1 Asymptomatic -2D echo shows good LVEF at least 50% despite LV hypertrophy; mild pericardial effusion no IVC or Stage C with moderate to severe LVED >5.5 but asymptomatic Otherwise, may need cardiology clearance	Expert Opinion

JOGY SOCIETY



President: Agnes A. Alarilla-Alba MD

Vice President: Violeta M. Valderrama MD

Secretary: Bettina C. Cercenia MD

Treasurer: Marvin C. Callanta, MD

**Board Members** 

Ma Angeles G. Marbella MD

Ma Lorna Lourdes L. Simangan, MD

Paul Joseph T. Galutira, MD

Regional Representative:

Lynette Fillone Alcala MD

**Immediate Past President** 

Maria Rosario F. Cabansag, MD:



# Committee on CPGs & Committee on Policy Statements

Chair: Ma Lorna Lourdes L Simangan, MD

Members:

Eric Emmanuel T. Aragon, MD

Nathan C. Bumanglag, MD

Coe P. dela Sena, MD

Catherine B. Dizon, MD

Ana Rose Dy-Vicente, MD

Dennis S. Flores, MD

Maria Theresa Garcia- Banez, MD

Maria Margarita M. Romano, MD

Lourdes Paula R. Resontoc, MD

Adviser: Agnes Alarilla-Alba, MD